Mayo Clinic home page [logo]

Search

  • Print
  • Share
close

Share this on...

Share this site with others using one of these sharing tools.

 

Link to this article

To link to this article, paste this block of HTML code onto your webpage.

Guidelines for sites linking to mayoclinic.org

Two Drugs Equally Effective for Heart Patients Undergoing Angioplasty, Mayo Study Finds

Monday, September 10, 2007

ROCHESTER, Minn. — In lifesaving procedures to open blocked heart arteries a key question has persisted for years: Is use of the more expensive drug, abciximab, justified over use of the less-expensive eptifibatide?

A new Mayo Clinic study to be published in the current edition of Value in Health, Volume 11, Issue 4 and now available as an e-publication, offers clinicians the first large-scale contemporary study to help answer the question. The study found no significant difference between the drugs in the length of hospital stay or in the rate of cardiovascular event rates.

"Our results provide data to show using the lower cost drug does not jeopardize patient health in contemporary percutaneous coronary intervention practice," explains the study's lead author, Kirsten Hall Long, Ph.D. Percutaneous coronary intervention (PCI), also known as angioplasty, is a procedure in which a balloon-tipped catheter is inserted into the narrowed vessel. The balloon is inflated and improves blood flow.

Researchers reviewed records of all Mayo Clinic patients who underwent PCI from November 2000 to August 2004. Of these, 2,123 patients received eptifibatide, and 951 received abciximab.

"It is not likely that there will ever be a randomized clinical trial comparing the two drugs, as it would require over 30,000 patients," says Henry Ting, M.D., Mayo Clinic cardiologist and co-author. "Our study fills an evidence gap by providing data to help guide treatment decisions."

Value in Health is a multidisciplinary peer-reviewed journal reporting on evaluations of medical technologies including pharmaceuticals, biologics, devices, procedures and other health care interventions. It provides a scientific forum for communicating health economics and outcomes research methods and findings. The journal is a publication of the International Society for Pharmacoeconomics and Outcomes Research.

###

About Mayo Clinic

Mayo Clinic is the first and largest integrated, not-for-profit group practice in the world. Doctors from every medical specialty work together to care for patients, joined by common systems and a philosophy of "the needs of the patient come first." More than 3,700 physicians, scientists and researchers and 50,100 allied health staff work at Mayo Clinic, which has sites in Rochester, Minn; Jacksonville, Fla; and Scottsdale/Phoenix, Ariz. and community based providers in more than 70 locations in Southern Minn., Western Wis. and Northeast Iowa. These locations treat more than half a million people each year. To obtain the latest news releases from Mayo Clinic, go to www.mayoclinic.org/news. For information about research and education, visit www.mayo.edu. MayoClinic.com is available as a resource for your health stories.

Contact Information

For more information, contact:

Traci Klein
507-284-5005 (days)
507-284-2511 (evenings)
newsbureau@mayo.edu

Patient & Visitor Guide

Learn more about becoming a patient at Mayo Clinic in the Patient & Visitor Guide.

Terms of Use and Information Applicable to this Site
Copyright ©2001-2009 Mayo Foundation for Medical Education and Research. All Rights Reserved.

.